US
US Precision Oncology Market Industry Trends and Forecast to 2034: Segmented by (Product, Cancer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $46.76 Bn.
Canada at 10.3% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$49.87 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $43.13 Bn | — | — |
| 2025 (base) | $46.76 Bn | +$3.62 Bn | — |
| 2026 (forecast) | $50.69 Bn | +$3.93 Bn | +8.4% |
| 2027 (forecast) | $54.94 Bn | +$4.26 Bn | +17.5% |
| 2028 (forecast) | $59.56 Bn | +$4.62 Bn | +27.4% |
| 2029 (forecast) | $64.56 Bn | +$5.00 Bn | +38.1% |
| 2030 (forecast) | $69.98 Bn | +$5.42 Bn | +49.7% |
| 2031 (forecast) | $75.86 Bn | +$5.88 Bn | +62.2% |
| 2032 (forecast) | $82.24 Bn | +$6.37 Bn | +75.9% |
| 2033 (forecast) | $89.14 Bn | +$6.91 Bn | +90.6% |
| 2034 (forecast) | $96.63 Bn | +$7.49 Bn | +106.7% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$46.76 Bn
Canada
$10.53 Bn
China
$10.57 Bn
Japan
$8.11 Bn
Germany
$4.66 Bn
Italy
$3.08 Bn
Brazil
$3.15 Bn
UK
$2.98 Bn
France
$2.72 Bn
India
$2.49 Bn
Spain
$2.31 Bn
Ecuador
$2.31 Bn
Saudi Arabia
$1.97 Bn
Mexico
$1.67 Bn
New Zealand
$1.28 Bn
Australia
$1.28 Bn
Russia
$1.10 Bn
South Africa
$676.5 Mn
UAE
$548.9 Mn
Egypt
$377.9 Mn
Philippines
$254.8 Mn
Malaysia
$181.0 Mn
Hong Kong
$169.5 Mn
Singapore
$139.6 Mn
Thailand
$123.8 Mn
Kenya
$90.3 Mn
Precision oncology matches cancer treatment to the genetic changes in a patient's tumour, using tests and targeted drugs.
Key segments of the precision Oncology market include product (Genomic Tests, Targeted Therapies and Informatics Platforms) and cancer (Lung, Breast and Colorectal).
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the precision Oncology market. Faster approvals and new combinations are improving survival.
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the precision Oncology market.
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the precision Oncology market, especially in low- and middle-income countries.
The precision Oncology market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for precision Oncology. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
What doctors and scientists are doing in Precision Oncology right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
US · 2 shared keywords
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US
Digital Health · US
Digital Health · US
Healthcare Services · US
Healthcare Services · US
Medical Devices · US
Digital Health · US